Sun Pharma gets USFDA nod for Generic Amphotericin B Liposome Injection

Published On 2021-12-17 05:39 GMT | Update On 2021-12-17 05:39 GMT

Mumbai: Sun Pharmaceutical Industries Limited has announced that one of its wholly-owned subsidiaries has received final approval from United States Food and Drug Administration (USFDA) for its Abbreviated New Drug Application (ANDA) for generic Amphotericin B Liposome for Injection, 50 mg/vial Single-Dose Vial.

The generic product approval is based on AmBisome Liposome for Injection, 50 mg/vial as a reference product.

"Sun Pharma has been granted Competitive Generic Therapy (CGT) designation by US FDA and being the first approved generic, is eligible for 180 days of CGT exclusivity for the product," the company said in a release.

As per October 2021 IQVIA Health data, AmBisome Liposome for Injection, 50mg/vial had annualized sales of approximately US$ 136 million in USA.

Sun Pharma is an Indian multinational pharmaceutical company headquartered in Mumbai, Maharashtra. The company manufacture and market a large basket of pharmaceutical formulations covering a broad spectrum of chronic and acute therapies. It includes generics, branded generics, specialty, complex or difficult to make technology-intensive products, over-the-counter (OTC), antiretrovirals (ARVs), Active Pharmaceutical Ingredients (APIs) and Intermediates.

Disclaimer: This website is primarily for healthcare professionals. The content here does not replace medical advice and should not be used as medical, diagnostic, endorsement, treatment, or prescription advice. Medical science evolves rapidly, and we strive to keep our information current. If you find any discrepancies, please contact us at corrections@medicaldialogues.in. Read our Correction Policy here. Nothing here should be used as a substitute for medical advice, diagnosis, or treatment. We do not endorse any healthcare advice that contradicts a physician's guidance. Use of this site is subject to our Terms of Use, Privacy Policy, and Advertisement Policy. For more details, read our Full Disclaimer here.

NOTE: Join us in combating medical misinformation. If you encounter a questionable health, medical, or medical education claim, email us at factcheck@medicaldialogues.in for evaluation.

Ruchika Sharma

Ruchika Sharma joined Medical Dialogue as an Correspondent for the Business Section in 2019. She covers all the updates in the Pharmaceutical field, Policy, Insurance, Business Healthcare, Medical News, Health News, Pharma News, Healthcare and Investment. She has completed her B.Com from Delhi University and then pursued postgraduation in M.Com. She can be contacted at editorial@medicaldialogues.in Contact no. 011-43720751

Comments Policy

Our comments section is governed by our Comments Policy . By posting comments at Medical Dialogues you automatically agree with our Comments Policy , Terms And Conditions and Privacy Policy .

Sun Pharma gets USFDA nod for Generic Amphotericin B Liposome Injection

Similar News

Jubilant Ingrevia appoints Sonia Dharap as Vice President - Sales, Business Development (US)

EMA warns of sharp rise in illegal medicines sold in EU

Indegene opens new center in Pune, boosts India presence

Indian medical devices share increased from 10% to 30% of domestic requirements in last 5 years: DoP Secretary

AstraZeneca announces Rs 176 crore investments in India to expand Chennai GITC

Eli Lilly gets USFDA Breakthrough Therapy designation for olomorasib with Keytruda for lung cancer

NPPA fixes Special Ceiling Price for Gufic's Meropenem Dual Chamber Bags

Sun Pharma Fails to Secure CDSCO Nod for BE, Phase III Waiver on Sitagliptin, Glimepiride, Metformin FDC